Five or 6 years ago, only 5% to 10% of patients at David Hong, MD,’s clinic arrived with a mutational profile of their tumor. Today, it’s more like 25% to 30%. They come bearing their tumor profile in the hope that they’ll qualify for one of a growing number of clinical trials targeting specific biomarkers, a strategy called precision medicine. Desperate, some come already knowing that they qualify for a particular trial, thanks to Facebook groups for cancer patients whose tumors share the same genetic abnormality and other online resources.
Rubin R. A Precision Medicine Approach to Clinical Trials. JAMA. 2016;316(19):1953-1955. doi:10.1001/jama.2016.12137